Bank Julius Baer & Co. Ltd, Zurich Arvinas, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$36.38 - $52.31 $67,303 - $96,773	1,850 Added 12.78%	16,330 $674,000
Q4 2023 May 16, 2024	SELL	$14.19 - $42.33 $21,568 - $64,341	-1,520 Reduced 9.5%	14,480 $595,000
Q4 2023 May 16, 2024	SELL	$14.19 - $42.33 $4,682 - $13,968	-330 Reduced 2.02%	16,000 $658,000
Q4 2023 Feb 02, 2024	BUY	$14.19 - $42.33 $205,471 - $612,938	14,480 New	14,480 $596,000
Q3 2022 Nov 04, 2022	BUY	$41.87 - $57.99 $89,769 - $124,330	2,144 New	2,144 $95,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.